Wegovy & Mounjaro
Understanding the difference between GLP-1 and dual-action therapies.
Backed by clinical data, delivered by Jace Medical.
Wegovy®
The Established GLP-1
Active Ingredient
Semaglutide
Mechanism
Single Receptor (GLP-1)
Clinical Weight Loss
Average ~15%
Device Type
FlexTouch Pen (4 Doses)
Mounjaro®
The Dual-Action Innovation
Active Ingredient
Tirzepatide
Mechanism
Dual Receptor (GLP-1 + GIP)
Clinical Weight Loss
Average ~21%
Device Type
KwikPen (Multi-use)
*Based on respective clinical trial data (STEP 1 & SURMOUNT-1). Individual results vary.
The Science: One Key vs. Two
Both medications mimic natural hormones, but they target different pathways in your metabolic system.
Wegovy (GLP-1)
Targets a single receptor in the brain to signal fullness and slow digestion. Think of it as a master key for satiety.
Mounjaro (GLP-1 + GIP)
Targets two receptors. It signals fullness AND improves how your body processes sugar and fat. Two keys for broader metabolic control.
Discreet Administration
Both treatments use simple, pre-filled injection pens.
FlexTouch
Weekly FlexTouch
- 1Attach needle
- 2Dial dose
- 3Inject (10s)
What about side effects?
Nausea & Digestion
Most common with both medications as your body adjusts to slower digestion.
Injection Site
Some Mounjaro users report slightly more redness or itching at the site than Wegovy users.
Clinical Support
We titrate your dose slowly. If side effects occur, our doctors adjust your plan immediately.
Common Questions
Can I switch from Wegovy to Mounjaro?
Which one works faster?
Is one more expensive?
Still unsure which is right for you?
Our clinical team will review your health profile and recommend the safest, most effective option.
Take the Eligibility Quiz